






  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="robots" content="noindex,nofollow"/>
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>Certolizumab in Crohn&apos;s Disease Patients With Loss of Response or Intolerance to Infliximab - Tabular View - ClinicalTrials.gov</title>
    <link href="/ct2/show/record/NCT00308581" rel="canonical"/>
  
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/jquery/css/superfish-vertical.css" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/base.css?v=b4" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/ct3/css/print.css" media="print" />
  <link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct.css" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/ct3/css/w3-ct-oldIE.css" type="text/css" />
  <![endif]-->
  	

     <!--[if lte IE 7]>
           <link href="/ct2/html/ct3/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
    <![endif]-->

<link href="/ct2/html/ct3/css/trial-record.css?v=b4" rel="stylesheet" type="text/css" />
<link href="/ct2/html/ct3/css/ct2Header.css" rel="stylesheet" type="text/css" />


	<script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.min.js?v=1.12.4"></script><noscript></noscript>
	    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/superclick.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/jquery/js/jquery.cookie.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/images/frame/ct.js"></script><noscript></noscript>
    <script type="text/javascript" src="/ct2/html/ct3/js/ctmenu.js?v=b4"></script><noscript></noscript>

    <script type="text/javascript" src="/ct2/html/images/foresee/foresee-trigger.js"></script><noscript></noscript>
<script type="text/javascript">
    $(window).load(function(){
        loadCTCommon();
        });
</script>
 


  <script type="text/javascript">
    ncbi_pingWithImage=true;
    __ncbi_stat_url="//www.ncbi.nlm.nih.gov/stat";        
  </script>
  
  <meta name="ncbi_sid" content="86171a44985d4bd6_812bdSID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_record"/>
  <meta name="ncbi_pcid" content="NCT00308581"/>
  <meta name="ncbi_ctreqid" content="RRd02Drk"/>
  <meta name="ncbi_ctsessid" content="SRd01hFv"/>
  <meta name="ncbi_ctipid" content="IzOkI5NS"/>
  <meta name="ncbi_cthost" content="wp3"/>
</head>

<body class="js one-column"> 
<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>

<script type="text/javascript">
	var RetractableBannerStateProperty = 'CT_NewsBannerState';
	
	ToggleBanner = function()
    {
        var theAccordion = $('#retractableBanner'); 
       	if (theAccordion.css("display") == "none") {
        		$('#showMore').css('visibility', 'hidden');
        	} else {
         		$('#showMore').css('visibility', 'visible');
        	}
        theAccordion.slideToggle({
            duration: 'fast',
            start: function(){
				            	if (typeof FuncReAlign !== 'undefined') {
            		$( "table.fixedHeader-floating" ).hide();
            	}
			},
            done: function(){
            	if (theAccordion.css("display") == "none") {
            		rememberRetractableBannerState('hide');
            	} else {
            		rememberRetractableBannerState('show');
            	}
            	if (typeof FuncReAlign !== 'undefined') {
                	FuncReAlign();  
            		$( "table.fixedHeader-floating" ).show();
            	}
            }
		});
    };
	    
	var rememberRetractableBannerState = function(newState) {
		try {
			sessionStorage.setItem(RetractableBannerStateProperty, newState);
		} catch (e) {}
	};

	$(window).ready(function(){
		try {
			var retractableBannerState = sessionStorage.getItem(RetractableBannerStateProperty);
					    if (retractableBannerState === null  || retractableBannerState === 'show') {
				ToggleBanner();
			}
		} catch (e) {};
	});
</script><noscript></noscript>
<div class="w3-container w3-center" style="padding:1.5ex 0.125in 0;background:#205493;color:white">
	<div style="font-weight:bold;">This site became the new ClinicalTrials.gov on June 19th. <a href="https://www.nlm.nih.gov/pubs/techbull/mj17/mj17_clinicaltrials_improve_usability.html" style="margin-left:1em;color:white;border-bottom-color:white;">Learn more.</a>
		<div id="showMore" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show more <img src="/ct2/html/ct3/images/show-more.png" style="width:17px;"></div>
	</div>
	<div id="retractableBanner" style="margin-top:1ex;display:none;">We will be updating this site in phases. This allows us to move faster and to deliver better services.
		<div id="showLess" style="float:right;cursor:pointer;border-bottom:1px dotted white;" onclick="ToggleBanner();">Show less <img src="/ct2/html/ct3/images/show-less.png" style="width:17px;"></div>
	</div>
</div>
<div id="wrapper" style="padding-top:0;">  <div id="longAlert" class="w3-hide-small" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study.  <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>
<div id="shortAlert" class="w3-hide-medium w3-hide-large" style="background-color:papayawhip;font-size:small;margin-bottom:1.5ex;">
	<img src="/ct2/html/ct3/images/warning.png" alt="ClinicalTrials.gov Menu" style="max-width:0.8rem;cursor:pointer;"/>
    <b>IMPORTANT</b>: Talk with a trusted healthcare professional before volunteering for a study. <a href="/ct2/about-site/disclaimer">Read more...</a>
</div>

  
	<div id="header" style="float:left;"> <a href="/ct2/home" style="border-style:none;box-shadow:none;"><img src='/ct2/html/ct3/images/ct.gov-logo.png' alt='ClinicalTrials.gov' style='max-width:100%;' /></a><br />
    	<div id="tagline">A service of the U.S. National Institutes of Health</div>
  	</div>
					<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/ct3/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
					</ul>
				</div>
    		</div>
  		</div>		

	  	<div id="savedStudies" style="float:right;padding:4px 8px;"> 		  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
		  	<button class="savedStudiesEnabled" id="open-cart-link" type="button" 
		  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
		  		title="Show previously saved studies.">Saved Studies</button>
		  	</div>
			<button class="savedStudiesDisabled" id="cart-disabled" type="button" disabled
				title="There are no saved studies to show. You can save studies to visit later from the search results page">Saved Studies (0)</button>
		</div>

		<div style="clear:right;text-align:right;padding-top:1ex;padding-right:8px;font-size:small;">
			<a href="https://survey.foreseeresults.com/survey/display?cid=WyHFr2m0PoaGCBUsi00QIQ==&sid=link-ct" target="_blank">Give us feedback</a></div>
		<script type="text/javascript" src="/ct2/html/ct3/js/cart.js?v=b4"></script><noscript></noscript>
  	
<div id="global-nav" class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
			<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/ct3/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 Requirements</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for an Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/ct3/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/ct3/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
	</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div> 

<div id="utilities">
     
</div>
<div id="breadcrumb">
	<ul class="horz-list">
		<li><a href="/ct2/home">Home</a></li>
				<li class="last">Study Record Detail</li>
	</ul>
</div>


<div id="main-content">


        	<h1 class="solo_record">Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab</h1>
	<div id="trial-info-1" class="floater-50">

     


      
        <div  class="not-recruiting-status" >
      This study has been completed.
          </div>
        
        
      
        




                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> UCB Pharma </div>



                              <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text">UCB Pharma</div>
              

            </div>
               <div id="trial-info-2" class="floater-50">
                <div class="info-title">ClinicalTrials.gov Identifier:</div>
                <div class="identifier">NCT00308581</div>
                <div class="info-date">First received: March 28, 2006</div>
                <div class="info-date">Last updated:  August 30, 2011</div>
                <div class="info-date">Last verified:  April 2011 </div>
                <div class="info-date"> <a href="/ct2/archive/NCT00308581"
          title="Historical versions of study NCT00308581 on ClinicalTrials.gov Archive Site - opens in new window"
          onclick="openNewWindow('/ct2/archive/NCT00308581'); return false;">History of Changes</a> </div>
            </div>



<div id="tabs">
        <ul id="tab-links">
			<li id="full-text" ><a href="/ct2/show/study/NCT00308581"  >Full Text View</a></li>
			<li id="tabular"     class="current"> Tabular View       </li>
			<li id="results"   ><a href="/ct2/show/results/NCT00308581">Study Results</a></li>
			<li id="disclaimer"><a href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
        </ul>
</div>  <div style="background-color:#f6f6f6;margin-top:3.5ex;padding-bottom:3.5ex;"> </div>




<!-- field list -->
<div class="indent1">
 
  <table class="w3-table data_table tableStyle">
    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Tracking Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">First Received Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">March 28, 2006</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Last Updated Date </th>
            <td class="body3 rowBody">August 30, 2011</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Start Date&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">April 2006</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">April 2008 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 14, 2010)</span></th>
            <td class="body3 rowBody">Response Status With Response Defined as at Least 100 Point Decrease in Crohn&apos;s Disease Activity Score (CDAI Score) From Baseline in the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 6&nbsp;]<div class="indent2" style="margin-top:1ex;"><p style="margin-top:0ex; margin-bottom:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score) from baseline, otherwise there is a non-response.</p>
<p style="margin-top:0ex; margin-bottom:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</p></div></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Primary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;March 28, 2006)</span></th>
            <td class="body3 rowBody">Assessment of Clinical efficacy of certolizumab pegol at week 6 based on CDAI score</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Change History </th>
            <td class="body3 rowBody"><a href="/ct2/archive/NCT00308581" onclick="openNewWindow('/ct2/archive/NCT00308581'); return false;">Complete list of historical versions of study NCT00308581 on ClinicalTrials.gov Archive Site</a></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;December 14, 2010)</span></th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Response Status With Response Defined as at Least 100 Point Decrease in CDAI Score From Baseline in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in CDAI score from baseline. The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 6&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Response Status With Response Defined as at Least 70 Points Reduction in CDAI Score in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 70 points reduction in CDAI score. The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Remission Status With Remission Defined as CDAI Score &#8804; 150 in the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 6&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150. The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Remission Status With Remission Defined as CDAI Score &#8804; 150 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150. The CDAI score is used to quantify the symptoms with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 2 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 2&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 4 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 4&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 6 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 6&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 8 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 8&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 10 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 10&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 12 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 14 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 14&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 16 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 16&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 18 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 18&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 20 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 20&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 22 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 22&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 24 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 24&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">CDAI Score at Week 26 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 2 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 2&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 4 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 4&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 6 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 6&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 8 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 8&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 10 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 10&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 12 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 12&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 14 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 14&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 16 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 16&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 18 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 18&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 20 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 20&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 22 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 22&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 24 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 24&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Change From Baseline in CDAI Score at Week 26 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Baseline to Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">The CDAI score is used to quantify the symptoms of subjects with Crohn&apos;s Disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease. A decrease in CDAI over time indicates improvement in disease activity.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 10&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 12&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 14&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 16&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 18&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 20&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 22&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 24&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Remission at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Remission is defined as CDAI score &#8804; 150.</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 10 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 10&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 12 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 12&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 14 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 14&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 16 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 16&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 18 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 18&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 20 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 20&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 22 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 22&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 24 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 24&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">Number of Patients Able to Taper and Discontinue Steroids While Maintaining Response at Week 26 in the Randomized Maintenance Phase in the Subset of Patients Taking Steroids at Baseline. [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">Response is defined as at least 100 point decrease in Crohn&apos;s Disease Activity Score (CDAI score).</div></li>
<li style="margin:1ex 0.5ex">C - Reactive Protein (CRP) Level at Baseline (Week 0) of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 0&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 2 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 2&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 4 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 4&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 6 of the Induction Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 6&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 8 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 8&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 10 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 10 (optional measurement)&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 12 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 12&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 14 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 14 (optional measurement)&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 16 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 16&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 18 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 18 (optional measurement)&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 20 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 20&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 22 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 22 (optional measurement)&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 24 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 24&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Week 26 in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L.</div></li>
<li style="margin:1ex 0.5ex">CRP Level at Endpoint (Last Visit) in the Randomized Maintenance Phase [&nbsp;Time&nbsp;Frame:&nbsp;Last visit on or before Week 26&nbsp;]<div class="indent2" style="margin-top:1ex;">High CRP levels are defined as greater or equal 5 mg/L, normal or low levels are below 5 mg/L. Endpoint is the visit when the last observation was taken, either at week 26 or at a visit before in case of early dropout.</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Secondary Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> <br/>&nbsp;<span class="footer">(submitted:&nbsp;March 28, 2006)</span></th>
            <td class="body3 rowBody">Assessment of clinical efficacy of certolizumab pegol and treatment response over 26 weeks</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Current Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Original Other Outcome Measures&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Descriptive Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Official Title&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Brief Summary </th>
            <td class="body3 rowBody">To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Detailed Description </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Type&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Interventional</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Phase </th>
            <td class="body3 rowBody">Phase 3</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Design&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Allocation: Randomized<br/>Intervention Model: Parallel Assignment<br/>Masking: Double Blind (Participant, Investigator)<br/>Primary Purpose: Treatment</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Condition&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Crohn's Disease</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Intervention&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Biological: Certolizumab pegol
<div class="indent2" style="margin-top:0.5ex">400mg Certolizumab Pegol, Q4W, administered 4-weekly</div>
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>CDP870</li>
<li>Cimzia</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Biological: Certolizumab pegol
<div class="indent2" style="margin-top:0.5ex">400mg Certolizumab Pegol, Q2W, administered 2-weekly</div>
<div class="indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>CDP870</li>
<li>Cimzia</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Other: Placebo
<div class="indent2" style="margin-top:0.5ex">placebo administered 4-weekly in Active 1</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Arms </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex">Experimental: Active 1
<div class="indent2" style="margin-top:0.5ex"><p style="margin-top:0ex; margin-bottom:1ex;">Q4W regimen</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">- every 4 weeks: alternatively placebo and 400mg Certolizumab Pegol</p></div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Certolizumab pegol</li>
<li>Other: Placebo</li>
</ul>
</div></li>
<li style="margin:1ex 0.5ex">Experimental: Active 2
<div class="indent2" style="margin-top:0.5ex"><p style="margin-top:0ex; margin-bottom:1ex;">Q2W regimen</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">- every 2 weeks: 400 mg Certolizumab Pegol</p></div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Certolizumab pegol</div></li>
</ul>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Publications * </th>
            <td class="body3 rowBody"><ul style="margin:0ex 1em; padding:0ex 0em">
<li style="margin:1ex 0.5ex"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0txR08xKCRA6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0txR08xKCRA6h9Ei4L3BUgWwNG0it.'); return false">Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E, Wolfe F, Schwartzman S, Furfaro N, Kavanaugh A. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J Int Med Res. 2010 Jul-Aug;38(4):1213-24.</a></li>
<li style="margin:1ex 0.5ex"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0tWgCjcg0RA6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0tWgCjcg0RA6h9Ei4L3BUgWwNG0it.'); return false">Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6.</a></li>
<li style="margin:1ex 0.5ex"><a class="study-link" href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0jSR0RFg4VA6h9Ei4L3BUgWwNG0it." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0jSR0RFg4VA6h9Ei4L3BUgWwNG0it.'); return false">Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011 Mar;33(5):541-50. doi: 10.1111/j.1365-2036.2010.04568.x. Epub 2011 Jan 12.</a></li>
</ul>
</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        * &nbsp; Includes publications given by the data provider as well as publications
        identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
      </td>
    </tr>

    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Recruitment Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Recruitment Status&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Completed</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Enrollment&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">539</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Completion Date </th>
            <td class="body3 rowBody">April 2008</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Primary Completion Date </th>
            <td class="body3 rowBody">April 2008 &nbsp; (Final data collection date for primary outcome measure)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Eligibility Criteria&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Subjects with Crohn's Disease</li>
    <li style="margin-top:0.7ex;">Previous treatment failure to Infliximab (intolerance and/or no response)</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Obstructive intestinal strictures</li>
    <li style="margin-top:0.7ex;">Recent bowel resection</li>
    <li style="margin-top:0.7ex;">Proctocolectomy or total colectomy</li>
    <li style="margin-top:0.7ex;">Current total parenteral nutrition</li>
    <li style="margin-top:0.7ex;">Short bowel syndrome</li>
    <li style="margin-top:0.7ex;">All concomitant diseases or pathological conditions that could interfere with Crohn's disease assessment or to be harmful for the well being of the patient</li>
    <li style="margin-top:0.7ex;">Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial</li>
  </ul></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Sex/Gender </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Sexes Eligible for Study:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">All</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Ages </th>
            <td class="body3 rowBody">18 Years and older &nbsp; (Adult, Senior)</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Accepts Healthy Volunteers </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Contacts&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><i style="color:#777777">Contact information is only displayed when the study is recruiting subjects</i></td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Listed Location Countries&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">Austria, &nbsp; Belgium, &nbsp; Canada, &nbsp; Denmark, &nbsp; France, &nbsp; Germany, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Norway, &nbsp; Spain, &nbsp; Sweden, &nbsp; Switzerland, &nbsp; United Kingdom, &nbsp; United States</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Removed Location Countries </th>
            <td class="body3"> &nbsp; </td>
          </tr>
    
    <tr><td colspan=2>&nbsp;</td></tr>

    <tr>
      <th class="header2 banner_color sectionBanner" colspan="2">Administrative Information</th>
    </tr>
        <tr>
      <th class="header3 banner_color rowHeader">NCT Number&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">NCT00308581</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Other Study ID Numbers&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">C87042<br> Eudract number: 2005-004104-37</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Has Data Monitoring Committee </th>
            <td class="body3 rowBody">No</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">U.S. FDA-regulated Product </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">IPD Sharing Statement </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Responsible Party </th>
            <td class="body3 rowBody">UCB Pharma</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Study Sponsor&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody">UCB Pharma</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Collaborators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="missing_color">Not Provided</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Investigators&nbsp;<sup style="color:blue"> ICMJE </sup> </th>
            <td class="body3 rowBody"><table class="layout_table" cellpadding="0" cellspacing="0" style="border:none;">
  <tr valign="top">
   <td style="padding:0px; margin:0ex; border:none;" nowrap>Study Director:</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">UCB Clinical Trial Call Center</td>
   <td style="padding:0px 0px 0px 1em; margin:0ex; border:none;">+1 877 822 9493 (UCB)</td>
  </tr>
</table>
</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">PRS Account </th>
            <td class="body3 rowBody">UCB Pharma</td>
          </tr>
        <tr>
      <th class="header3 banner_color rowHeader">Verification Date </th>
            <td class="body3 rowBody">April 2011</td>
          </tr>
    
    <tr>
      <td class="header3" style="padding-left:2em" colspan="2">
        <br/>
        <sup style="color:blue"> ICMJE </sup>&nbsp; &nbsp; Data element required by the
        <a href="http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html">
        International Committee of Medical Journal Editors</a> and the
        <a href="http://www.who.int/ictrp/network/trds/en/index.html">World Health Organization ICTRP</a>
      </td>
    </tr>

  </table>
</div>


<div id="to-top"><a href="#wrapper">To Top</a></div>

	<div style="clear:both;"></div>
</div> 

      <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

<div id="footer-menu">
    <ul class="horz-list">
		<li><a href="/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a     href="/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a         href="/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a       href="/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a        href="https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00308581" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/ics/support/KBList.asp?folderID=146?style=classic&amp;deptID=28054&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Frecord%2FNCT00308581'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li                  ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li                  ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li                  ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li                  ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li                  ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

    <script type="text/javascript" src="/ct2/html/ct3/js/instrumentNCBIBaseJS.min.js"></script><noscript></noscript>

</body>
</html>
